DK189189D0 - AZELASTIC CONTAINED ACTIVE SUBSTANCES WITH CONTROLS - Google Patents

AZELASTIC CONTAINED ACTIVE SUBSTANCES WITH CONTROLS

Info

Publication number
DK189189D0
DK189189D0 DK189189A DK189189A DK189189D0 DK 189189 D0 DK189189 D0 DK 189189D0 DK 189189 A DK189189 A DK 189189A DK 189189 A DK189189 A DK 189189A DK 189189 D0 DK189189 D0 DK 189189D0
Authority
DK
Denmark
Prior art keywords
azelastic
controls
azelastine
active substances
release
Prior art date
Application number
DK189189A
Other languages
Danish (da)
Other versions
DK172235B1 (en
DK189189A (en
Inventor
Helmut Hettche
Original Assignee
Asta Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Pharma Ag filed Critical Asta Pharma Ag
Publication of DK189189D0 publication Critical patent/DK189189D0/en
Publication of DK189189A publication Critical patent/DK189189A/en
Application granted granted Critical
Publication of DK172235B1 publication Critical patent/DK172235B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585Ion exchange resins, e.g. polystyrene sulfonic acid resin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5026Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5036Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators

Abstract

Azelastine-containing pharmaceutical compositions with controlled release of active substance using a release-delaying component, there being 0.001 to 800 parts of release-delaying component for one part by weight of azelastine (as base), and it also being possible for the azelastine to be in the form of its physiologically tolerated salts, and the rate of azelastine release being between 0.05 and 5 mg per hour.
DK189189A 1988-04-20 1989-04-19 Azelastine-containing controlled-release drug DK172235B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3813244 1988-04-20
DE3813244 1988-04-20

Publications (3)

Publication Number Publication Date
DK189189D0 true DK189189D0 (en) 1989-04-19
DK189189A DK189189A (en) 1989-10-21
DK172235B1 DK172235B1 (en) 1998-02-02

Family

ID=6352451

Family Applications (1)

Application Number Title Priority Date Filing Date
DK189189A DK172235B1 (en) 1988-04-20 1989-04-19 Azelastine-containing controlled-release drug

Country Status (15)

Country Link
EP (1) EP0338444B1 (en)
JP (1) JP2950845B2 (en)
AT (1) ATE97572T1 (en)
AU (1) AU3318389A (en)
CA (1) CA1325976C (en)
DE (1) DE58906232D1 (en)
DK (1) DK172235B1 (en)
ES (1) ES2060685T3 (en)
FI (1) FI891865A (en)
HK (1) HK134494A (en)
HU (1) HU202403B (en)
IE (1) IE62778B1 (en)
MC (1) MC2025A1 (en)
PT (1) PT90308B (en)
ZA (1) ZA892877B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9003903D0 (en) * 1990-12-07 1990-12-07 Astra Ab NEW PHARMACEUTICAL FORMULATIONS
DE4207234A1 (en) * 1992-03-07 1993-09-09 Asta Medica Ag NEW AMINOCARBONIC ACID DERIVATIVES WITH ANTIALLERGIC / ANTIASTHMIC EFFECT AND METHOD FOR THE PRODUCTION THEREOF
JPH0710747A (en) * 1993-04-28 1995-01-13 Takeda Chem Ind Ltd Solid preparation and its production
GB9514842D0 (en) * 1995-07-20 1995-09-20 Smithkline Beecham Plc Novel formulation
JP4138910B2 (en) * 1997-07-02 2008-08-27 帝國製薬株式会社 Transdermal preparation containing azelastine hydrochloride with good transdermal absorbability and low skin irritation
UA67802C2 (en) * 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. CONTROLLED-RELEASE FORMULATIONS FOR ORAL ADMINISTRATION CONTAINING cGMP PDE-5 INHIBITOR (VARIANTS), METHOD FOR ITS PREPARATION AND METHOD FOR TREATING ERECTILE DYSFUNCTION
PT1126826E (en) 1998-11-02 2008-11-25 Elan Pharma Int Ltd Multiparticulate modified release composition of methylphenidate
KR101476574B1 (en) 1999-10-29 2014-12-24 유로-셀티크 소시에떼 아노뉨 Controlled release hydrocodone formulations
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
MXPA03003895A (en) 2000-10-30 2003-07-28 Euro Celtique Sa Controlled release hydrocodone formulations.
EP1396263A1 (en) * 2002-08-09 2004-03-10 Warner-Lambert Company Film coating for tablets and caplets
CA2510320C (en) * 2002-12-20 2012-10-09 St. James Associates Llc/Faber Research Series Coated particles for sustained-release pharmaceutical administration
EP2486942B1 (en) * 2004-11-24 2018-10-10 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
AU2014235854B2 (en) 2013-03-21 2019-04-11 Eupraxia Pharmaceuticals USA LLC Injectable sustained release composition and method of using the same for treating inflammation in joints and pain associated therewith
PL3206672T3 (en) 2015-10-27 2018-09-28 Eupraxia Pharmaceuticals Inc. Sustained release formulations of local anesthetics

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3575135D1 (en) * 1984-09-14 1990-02-08 Asta Pharma Ag SUBSTITUTED BENZYLPHTHALAZINONE DERIVATIVES.

Also Published As

Publication number Publication date
DK172235B1 (en) 1998-02-02
EP0338444B1 (en) 1993-11-24
PT90308A (en) 1989-11-10
DE58906232D1 (en) 1994-01-05
FI891865A (en) 1989-10-21
AU3318389A (en) 1989-10-26
MC2025A1 (en) 1990-04-25
ATE97572T1 (en) 1993-12-15
ES2060685T3 (en) 1994-12-01
CA1325976C (en) 1994-01-11
DK189189A (en) 1989-10-21
JP2950845B2 (en) 1999-09-20
EP0338444A1 (en) 1989-10-25
IE62778B1 (en) 1995-02-22
ZA892877B (en) 1989-12-27
IE891263L (en) 1989-10-20
FI891865A0 (en) 1989-04-19
PT90308B (en) 1994-10-31
HUT49808A (en) 1989-11-28
HU202403B (en) 1991-03-28
JPH01311024A (en) 1989-12-15
HK134494A (en) 1994-12-09

Similar Documents

Publication Publication Date Title
DK189189A (en) AZELASTIC CONTAINED ACTIVE SUBSTANCES WITH CONTROLS
DK0449247T3 (en) Pharmaceutical formulation containing galanthamine for the treatment of alcoholism
ATE76747T1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING LEVODOPA METHYL ESTER, THEIR PREPARATION AND THERAPEUTIC USES.
PT615754E (en) SOLID FORMS OF CONTROLLED LIBERATION ORAL ADMINISTRATION FLUPERTINE
GR1003711B (en) Method for preparating pharmaceutical compositions for diadermic use
DK367687D0 (en) PHARMACEUTICAL PREPARATION FOR ORAL ADMINISTRATION WITH REGULATED DELIVERY AND EXTENDED EFFECT
DK1308170T3 (en) Dried blood factor preparation containing trehalose
ATE148630T1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING STABILIZED DERIVATIVES OF VITAMIN D2 AND D3
DK373187A (en) MEDICINAL WITH SLOW RELEASE OF THE ACTIVE INGREDIENT
DK0458588T3 (en) Treatment of ocular hypertension with a synergistic combination for ocular administration
NO821084L (en) PROCEDURE FOR PREPARING GALENIC PREPARATION WITH CONSTANT ACTUAL RELEASE
DK386986A (en) INJECTABLE semi-solid pharmaceutical formulation with slow release of the active ingredient
DK122191A (en) BENZIMIDAZOLD DERIVATIVES AND PHYSIOLOGICALLY ACCEPTABLE SALTS THEREOF, AND PROCEDURES FOR THE PREPARATION OF SAME
DE3783923T3 (en) A drug containing an active ingredient and a water-swelling polymer.
EP0380989A3 (en) Plaster for transdermal administration
ES2043719T3 (en) DRUG ADMINISTRATION BY VIA PERCUTANEA.
EP0351876A3 (en) Composition for potentiating vaccination effect
DK0521353T3 (en) Antineoplastic drug containing octadecyl (2- (N-methylpiperidino) ethyl) phosphate as an active ingredient and process for its preparation
TH7154EX (en) Celastine contained in therapeutic agents that regulate the release of active metabolites.
DK0560207T3 (en) Preparation for oral use based on ibuprofen

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
PUP Patent expired